TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch
TG Therapeutics (TGTX) shares rose 5% after Bank of America raised its price target to $20 from $17, despite an 'Underperform' rating. The company launched a mid-stage trial for Briumvi in treatment-resistant schizophrenia. Analysts focus on Q2 U.S. revenue for Briumvi, with estimates around $229M, exceeding the company's $220M guidance. TGTX has gained 95% year-to-date.
How this was made
The 30-second read
Why it matters
Analyst upgrade and trial launch provide fresh catalysts that could affect short‑term price action.
Market read
New trial and price‑target change create a near‑term trading opportunity for TGTX.
What to watch
Briumvi's existing MS market may limit upside if schizophrenia indication stalls.
Background
TGTX is a biotech focused on Briumvi, an approved MS therapy now being tested for new indications.
Ticker impact
Bank of America raised TGTX price target to $20 and the company launched a mid‑stage schizophrenia trial for Briumvi.
Potential modest upside if trial data are positive; watch for further price‑target revisions.
The price‑target increase signals analyst confidence, and a new indication expands the drug's market potential.
Market effects
May lift sentiment for biotech firms developing repurposed therapies.
US biotech sector could see modest gains.
Limited to investors tracking US biotech pipelines.
Counterpoint
Trial failure risk remains high; price‑target hike may be premature.
Key entities
- AnalystBank of America
Raised price target for TGTX.
- CEOMichael Weiss
Commented on the schizophrenia trial rationale.
